3Kimbedy AP,Adrian V,Geoffrey BT,et al.Secular Trends in the Present-ation and Management of Functioning Insulinoma at the Mayo Clinic, 1987-2007[J].J Clin Endocrinol Metab, 2009,94 (4):1069-1073.
6Wiesli P,Brandh M,Sehmid C,et al.Selective arterial calcium stimulation and hepatic/erlott sampling in the evaluation of hyperinsulinemie hypoglycemia:potential and limitations[J].J Vase Interv Radiol,2004,15(11):1251-1256.
7Hirshberg B,Libutti SK,Alexander HR,et al.Blind distal pancreatectomy for occult insulinoma,an inadvisable procedure[J].J Am Coil Sag,2002.194(6):761-764.
8Lo CY,Chart WF,Lo CM,et al.Surgocal treatment of pancreatic imulinomas in the era of lapamecoy[J].Surg Endoec,2004,18(2):297-302.
9Tucker ON,Crotty PL,Cordon KC.The management of insrdinoma[J].Br J Surg,2006,93(3):264-275.
10Hirshberg B,Cechran C,SkandisMC,etal.Malignant inanlinoma:spectrum of unusual clinical features[J].Cancer,2005,104(2):264-272.
4Senn J J,Klover P J,Nowak I A. et al. Suppressor of cytokinesignaling 3(SOCS~3),a potential mediator of interleukin-6-de-pendent insulin resistance in hepatocytes [ J]. J Biol CKem,2003,278:13740-13746.
5Ueki K,Kondo T,Kahn C R. Suppressor of cytokine signaling1 ( SOCS-1) andSOCS-3 cause insulin resistance through inhibi-tion of tyrosine phosphorylationof insulin receptor substrateproteins by discrete mechanisms[J]. Mol Cell Biol, 2004 , 24 :5434-5446.
